Reshaping the future of nanopharmaceuticals: Ad iudicium

S. Moein Moghimi; Dan Peer; Robert Langer

doi:https://doi.org/10.1021/nn2038252

Reshaping the future of nanopharmaceuticals: Ad iudicium

S. Moein Moghimi, Dan Peer, Robert Langer

The Shmunis School of Biomedicine and Cancer Research

Tel Aviv University

Research output: Contribution to journal › Review article › peer-review

Abstract

We present views on the future development of biologics-based nanopharmaceuticals from a "high risk-high gain" perspective and within the context of personalized therapies. Integrated scientific, commercial, and societal aspects are addressed, and provocative combined realistic biotech, computational, and nanotech approaches for tailor-made engineering of nanopharmaceuticals are discussed.

Original language	English
Pages (from-to)	8454-8458
Number of pages	5
Journal	ACS Nano
Volume	5
Issue number	11
DOIs	https://doi.org/10.1021/nn2038252
State	Published - 22 Nov 2011

All Science Journal Classification (ASJC) codes

General Engineering
General Materials Science
General Physics and Astronomy

Access to Document

https://doi.org/10.1021/nn2038252

Cite this

@article{9337f51b192f43728cd293bd35186908,

title = "Reshaping the future of nanopharmaceuticals: Ad iudicium",

abstract = "We present views on the future development of biologics-based nanopharmaceuticals from a {"}high risk-high gain{"} perspective and within the context of personalized therapies. Integrated scientific, commercial, and societal aspects are addressed, and provocative combined realistic biotech, computational, and nanotech approaches for tailor-made engineering of nanopharmaceuticals are discussed.",

author = "Moghimi, {S. Moein} and Dan Peer and Robert Langer",

year = "2011",

month = nov,

day = "22",

doi = "https://doi.org/10.1021/nn2038252",

language = "الإنجليزيّة",

volume = "5",

pages = "8454--8458",

journal = "ACS Nano",

issn = "1936-0851",

publisher = "American Chemical Society",

number = "11",

}

TY - JOUR

T1 - Reshaping the future of nanopharmaceuticals

T2 - Ad iudicium

AU - Moghimi, S. Moein

AU - Peer, Dan

AU - Langer, Robert

PY - 2011/11/22

Y1 - 2011/11/22

N2 - We present views on the future development of biologics-based nanopharmaceuticals from a "high risk-high gain" perspective and within the context of personalized therapies. Integrated scientific, commercial, and societal aspects are addressed, and provocative combined realistic biotech, computational, and nanotech approaches for tailor-made engineering of nanopharmaceuticals are discussed.

AB - We present views on the future development of biologics-based nanopharmaceuticals from a "high risk-high gain" perspective and within the context of personalized therapies. Integrated scientific, commercial, and societal aspects are addressed, and provocative combined realistic biotech, computational, and nanotech approaches for tailor-made engineering of nanopharmaceuticals are discussed.

UR - http://www.scopus.com/inward/record.url?scp=81855218204&partnerID=8YFLogxK

U2 - https://doi.org/10.1021/nn2038252

DO - https://doi.org/10.1021/nn2038252

M3 - مقالة مرجعية

SN - 1936-0851

VL - 5

SP - 8454

EP - 8458

JO - ACS Nano

JF - ACS Nano

IS - 11

ER -

Reshaping the future of nanopharmaceuticals: Ad iudicium

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this